Today we are pleased to announce that Continuum Analytics and Recursion Pharmaceuticals are teaming up to use data science in the quest to find cures for rare genetic diseases. Using Bokeh on Anaconda, Recursion is building its drug discovery assay platform to analyze layered cell images and weigh the effectiveness of different remedies. As we always say, Anaconda arms data scientists with superpowers to change the world. This is especially valuable for Recursion, since success literally means saving lives and changing the world by bringing drug remedies for rare genetic diseases to market faster than ever before.
 
It’s estimated that there are over 6,000 genetic disorders, yet many of these diseases represent a small market. Pharmaceutical companies aren’t usually equipped to pursue the cure for each disease. Anaconda will help Recursion by blending biology, bioinformatics and machine learning, bringing cell data to life. By identifying patterns and assessing drug remedies quickly, Recursion is using data science to discover potential drug remedies for rare genetic diseases. In English – this company is trying to cure big, bad, killer diseases using Open Data Science. 

The ODS community is important to us. Working with a company in the pharmaceutical industry, an industry that is poised to convert ideas into life-saving medications, is humbling. With so many challenges, not the least of which include regulatory roadblocks and lengthy and complex R&D processes, researchers must continually adapt and innovate to speed medical advances. Playing a part in that process? That’s why we do what we do. We’re excited to welcome Recursion to the family and observe as it uses its newfound superpowers to change the world, one remedy at a time.

Want to learn more about this news? Check out the press release, here


About the Author

We help people discover, analyze, and collaborate by connecting their curiosity and experience with any data. It all comes together here. Anaconda gives superpowers to people who change the world.

Read more

Join the Disucssion